1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce

Pivotal Plans In The Works

 
• By Ayisha Sharma

The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.  

doctor measuring patient's waistline
There Could Be More Than 2.7 Billion Overweight Adults In 2025 • Source: Shutterstock

Boehringer Ingelheim GmbH and Zealand Pharma A/S’s weight loss drug candidate, BI 456906, has met the primary endpoint in a Phase II obesity trial but peak sales expectations remain low relative to first-in-class products from Novo Nordisk A/S and Eli Lilly and Company.

The trial set four undisclosed doses of BI 456906 – “very low,” “low,” “medium” and “high” – against placebo in obese or overweight adult subjects without type 2 diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.